India markets open in 1 hour 54 minutes
  • BSE SENSEX

    52,443.71
    -135.05 (-0.26%)
     
  • Nifty 50

    15,709.40
    -37.05 (-0.24%)
     
  • Dow

    34,930.93
    -127.59 (-0.36%)
     
  • Nasdaq

    14,762.58
    +102.01 (+0.70%)
     
  • BTC-INR

    2,955,053.25
    +382.25 (+0.01%)
     
  • CMC Crypto 200

    929.66
    -0.27 (-0.03%)
     
  • Hang Seng

    25,984.82
    +510.94 (+2.01%)
     
  • Nikkei

    27,752.29
    +170.63 (+0.62%)
     
  • EUR/INR

    88.1922
    -0.0665 (-0.08%)
     
  • GBP/INR

    103.5054
    -0.0847 (-0.08%)
     
  • AED/INR

    20.2060
    -0.0330 (-0.16%)
     
  • INR/JPY

    1.4715
    -0.0010 (-0.07%)
     
  • SGD/INR

    54.8670
    -0.0740 (-0.13%)
     

Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference

·2-min read

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president will participate in a fireside chat at the Raymond James Human Health Innovation Conference, taking place virtually on Monday, June 21, 2021 at 12:40 p.m. ET.

A webcast of the fireside chat will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contacts:

Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com

Julie Seidel
Stern Investor Relations
+1-212-362-1200
Julie.Seidel@sternir.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting